💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rivastigmine

CHEMBL636 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
250.3 g/mol
LogP
2.3
Phase
4

A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.

น้ำหนักโมเลกุล

250.3400 g/mol

LogP

2.30

TPSA

32.80 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Generalized Anxiety Disorder Multiple Sclerosis Stroke Major Depressive Disorder

กลไกการออกฤทธิ์

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H22N2O2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
พันธะที่หมุนได้

                        
5

                    

                    
                    
                    

                        
อะตอมหนัก

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Rivastigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL636.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 77991.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.